Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- “Some Aspects Might Have Been Overlooked” in Actavis Adaptation Scenario: ASKA President Yamaguchi
May 31, 2012
- CJ CheilJedang of Korea to hold R&D Forum with 6 Ventures in Japan
May 31, 2012
- Kyowa Kirin Launches Its First Antibody Drug Poteligeo for ATL
May 31, 2012
- Pfizer Launches ALK Inhibitor Xalkori, Administered to 51 Patients Prior to NHI Price Listing
May 30, 2012
- Kyorin Holdings to Boost Manufacturing System with Transfer of MSD Plant
May 30, 2012
- Shionogi Launches Oxycodone Injections in Response to Request for Development
May 30, 2012
- Takeda Launches ARB Azilva; Will Target Patients Inadequately Controlled with Existing Medications
May 30, 2012
- Cardiovascular Agent Market Increases 2.6% to 1.363 Billion Yen in 2011: Fuji-Keizai
May 30, 2012
- Takeda to Acquire Multilab of Brazil to Boost Business Infrastructure through OTC Drugs
May 29, 2012
- CMIC Subsidiary to Expand Non-Clinical Operations by Business Transfer
May 29, 2012
- Chugai Files NDA for Breast Cancer Treatment Pertuzumab in Japan
May 29, 2012
- Sanofi-aventis Applies for Switch OTC Allegra, PAFSC Committee to Review on June 7
May 28, 2012
- 26 TSE 1st-Section Drug Makers Post Overall Decline in Sales, Profits for FY2011: JPMA
May 28, 2012
- Meiji Seika Pharma Aims to Increase No. of MRs to 900 as Soon as Possible
May 28, 2012
- Nearly 30% Use “Only Neostigmine”: Neuromuscular Antagonists Usage Survey
May 28, 2012
- US Subsidiary of DSP Settles COPD Drug Patent Infringement Suit
May 28, 2012
- DPP-4 Inhibitors Gain Traction, Boosting Diabetes Market by 15.5%: IMS Japan
May 25, 2012
- Zeria Projects 19% Increase in Asacol Sales to 12.2 Billion Yen in FY2012
May 25, 2012
- Japanese Ethical Drug Market Expands by 5.5% to 9.5348 Trillion Yen: IMS Japan
May 25, 2012
- Takeda Files MAA for Alogliptin in Europe
May 25, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…